References
1. Zhdankin A.E., Ushakova G.A Structural and functional characteristic of ganglioside. Molodij vchenij [Young Scientist]. 2014; 11 (14): 258-62. (in Russian)
2. Schnaar R.L., Gerardy-Schahn R. Sialic acid in the brain: Gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev. 2014; 94 (2): 461-518.
3. Krepe E.M. Lipids of cell membranes. Leningrad: Nauka; 1981: 339 p. (in Russian)
4. Avrova N.F., Karpova O.B., Nalyvayeva N.N. Content and composition of gangliosides from nervous of a sea urchin strongl yocentrotus interme-dius. Journal of Evolutionary Biochemistry and Physiology. 1983; 19: 127.
5. McDaniel R., McLaughlin S. The interaction of calcium with gangliosides in bilayer membranes. Biochem Biophys Acta. 1985; 819 (2): 153-60.
6. Ledeen, R.W. Nuclear sphingolipids: Metabolism and signaling. Lipid Res. 2008; 49: 1176-86.
7. Nowycky M.C., Wu G., Ledeen R.W. Glycobiology of ion transport in the nervous system. Adv Neurobiol. 2014; Vol. 9: 321-42.
8. Mahadic S.P., Hawver D.B., Hangung B.K., et al. GM1 ganglioside treatment after global ischemia protects changes in membrane fatty acids. In: Calne D.B. (ed) Neurodegenerative deseases. Philadelph, Saunders, Harcourt, Brace and World. 1994; 277-99.
9. Toffano G.E. Savoini G., Moroni F., et al. Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat. Brain Res. 1984; 256 (2): 233-9.
10. Polak J.M., Bloom S.R. The diffuse neuroendocrine system. Studies of this newly discovered controlling system in health and disease. J Histochem Cytochem. 1979; 27 (10): 1398-400.
11. Tumanova S.Yu., Prokhorova M.I. Participation of gangliosides in neuronal membrane modification. Nejrohimija [Neurochemistry]. 1982; 1 (2): 184-99. (in Russian)
12. Glebov R.P., Kryzhanovskij G.N. Functional biochemistry of synapses. Moscow: Meditsina, 1978: 323 p. (in Russian)
13. Svennerholm L. Biological significance of gangliosides. In: Cellular and pathological aspects of glycoconjugate metabolism. Eds by H. Dreyfus, et al. Paris: Inserm, 1984: 21-44.
14. Wang B., Brand-Miller J. The role and potential of sialic acid in human nutrition. Eur J Clin Nutr. 2003; 57: 1351-69.
15. McJarrow P., Schnell N., Jumpsen J. Influence of dietary ganglio-sides on neonatal brain development Clandinin. Nutrition Reviews. 2009; 67 (8):451-63.
16. Mavlikhanova A.A., Pavlov V.N., Yang B., Kataev V.A., et al. Gangliosides and their significance in the development and functioning of the nervous system. Medicinskij vestnik Bashkortostana [Bashkortostan Medical Journal]. 2017; 12 (4): 121-6. (in Russian)
17. Svennerholm L., Bostrom K., Fredman P., Mansson J.E., et al. Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta. 1989; 1005 (2): 109-17.
18. Segler-Stahl K., Webster J.C., Brunngraber E.G. Changes in the concentration and composition of human brain gangliosides with aging. Gerontology. 1983; 29: 161-8.
19. Svennerholm L. Chromatographic separation of human brain gan-gliosides. J Neurochem. 1963; 10: 613-23.
20. Rueda R. The role of dietary gangliosides on immunity and the prevention of Infection. Br J Nutr. 2007; 98 (1): 68-73.
21. Park E.J., Suh M., Ramanujam K., Steiner K., et al. Diet-induced changes in membrane gangliosides in rat intestinal mucosa, plasma and brain. J Pediatr Gastroenterol Nutr. 2005; 40: 487-95.
22. Ruhl A. Glial cells in the gut. Neurogastroenterol Motil. 2005; 17: 777-90.
23. Wang J., Cheng A. Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain. J Neurosci. 2014; 34: 13790-800.
24. Tajima 0. Reduced motor and sensory functions and emotional response in GM3-only mice: Emergence from early stage of life and exacerbation with aging. Behav Brain Res. 2009; 198: 74-82.
25. Simpson M.A. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet. 2004; 36: 1225-9.
26. Schneider J.S., Gollomp S.M., Sendek S., Colcher A., et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci. 2013; 324: 140-8.
27. Geisler F.H., Coleman W.P., Grieco G., Poonian D. The Sygen multicenter acute spinal cord injury study. Spine. 2001; 26: 87-98.
28. Xi Ai-ping, Xu Zhong-xin, Liu Feng-li, Xu Yan-li. Neuroprotective effects of monosialotetrahexosylganglioside. Neural Regen Res. 2015; 10: 1343-4.
29. Van Heyningen W.E., Miller P.A. The fixation of tetanus toxin by ganglioside. J Gen Microbiol. 1961; 24: 107-19.
30. Swaminathan S. Molecular structures and functional relationships in clostridial neurotoxins. J. FEBS. 2011; 278: 4467-85.
31. Benson M.A., Fu Z., Kim J.J., Baldwin M.R. Unique ganglioside recognition strategies for clostridial neurotoxins. J Biol Chem. 2011; 286: 34015-22.
32. Connell T.D. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 6. 2007: 821-34.
33. Fukuta S., Magnani J.L., Twiddy E.M., Holmes R.K., et al. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun. 1988; 56: 1748-53.
34. Efremenko V.I., Narbutovich N.I., Khodova N.F. et al. Gangliosids -receptors of bacterial toxins and other biologically active agents. In: The annotated bibliographic index of russian and foreign literature 1976-1986. Volgograd, 1988; 202. (in Russian)
35. Tanabe A., Matsuda M., Fukuhara A., Miyata Y., et al.Obesity causes a shift in metabolic flow of gangliosides in adipose tissues. Biochem Biophys Res Commun. 2009; 379: 547-52.
36. Coleman R.A. The role of placenta in lipid metabolism. Seminars Perinatol. 1989; 13: 180-91.
37. Das T., Sa G., Mukherjea M. Characterization of cardiac fatty acidbinding protein from human placenta. Comparison with placenta heaptic types. Eur J Biochem. 1993; 211: 725-30.
38. Gustavsson M., Hodgkinson S.C., Fong B., Norris C., et al. Maternal supplementation with a complex milk lipid mixture during pregnancy and lactation alters neonatal brain lipid composition but lacks effect on cognitive function in rats. Nutr Rew. 2010; 30: 279-89.
39. Ukraintsev S.E., McJarrow P. Food and development of a brain: modern representations and prospection. Pediatrija [Pediatrics]. 2012; 91 (1): 101-7. (in Russian)
40. Fedorova L.A. Clinical significance of milk fat globule membranes in the nutrition of newborns and infants. Neonatologiya: novosti, mneniyz, obuchenie [Neonatology: News, Opinions, Training]. 2018; 6 (4): 49-57. (in Russian)
41. Ando S. Gangliosides in the nervous system. Neurochem Int. 1983; 5: P. 507-37.
42. Rueda R, Gil A. Role of gangliosides in infant nutrition. In: Huang Y.-S., Sinclair A.J. Lipids in infant nutrition. 1998. Champaign, IL, A0CS Press: 213-34.
43. Vainer M.T., et al. Developmental profiles of gangliosides in human and brain. J Neurochem. 1971. Vol.18. P. 581-592.
44. Rueda R, Tabsh K, Ladisch S. Detection of complex gangliosides in human amniotic fluid. FEBS Lett. 1993; 328: 13-6.
45. Li R., Ladisch S. Shedding of human neuroblastoma gangliosides. Biomed Biochim Acta. 1991; 1083: 57-64.
46. Laegreid A., Otnaess A.B.K. Trace amounts of ganglioside GM1 in human milk inhibits enterotoxin from Vibrio cholerae and Escherichia coli. Life Sci.1987; 40: 55-62.
47. Rueda R., Maldonaldo J., Narbona E., Gil A. Neonatal dietarygan-gliosides. Early Hum Dev. 1998; 53 (Suppl): 135-47.
48. Teneberg S., Willemsen P., de Graaf F.K., Karlsson K.A. Calf small intestine receptors for K99 fimbriated enterotoxigenic Escherichia coli. FEMS Microbiol Lett. 1993; 109: 107-12.
49. Idota T., Kawakami H., Nakajima I. Growth-promoting effects of N-acetylneuraminic acid-containing substances on bifidobacteria. Biosci Biotech Biochem. 1994; 58: 1720-2.
50. Schnabl K.L., Larcelet M., Thomson A.B., Clandinin M.T. Uptake and fate of ganglioside GD3 in human intestinal Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2009; 297: 52-9.
51. Schnabl K.L., Larsen B., Van Aerde J.E., Lees G., et al. Gangliosides protect bowel in an infant model of necrotizing enterocolitis by suppressing proinflammatory signals. J Pediatr Gastroenterol Nutr. 2009; 49: 382-92.
52. Miklavcic J.J., Schnabl K.L., Mazurak V.C., Thomson A.B., et al. Dietary ganglioside reduces proinflammatory signalling in the intestine. J Nutr Metabol. 2012; 2012: 280-6.
53. Yuasa H., Scheinberg D.A., Houghton A.N. Gangliosides of T lymphocytes: evidence for a role in T-cell activation. Tissue Antigens. 1990; 36: 47-56.
54. Nakamura K., Suzuki H., Hirabayashi Y., Suzuki A. IV alpha (NeuGc alpha 2-8NeuGc)-Gg4Cer is restricted to CD4+ T cells producing interleukin-2 and a small population of mature thymocytes in mice. J Biol Chem. 1995; 270: 3876-81.
55. Ebel F., Scmitt E., Peter-Katalinic J., Kniep B., et al. Gangliosides: differentiation markers for murine T helper lymphocyte subpopulations TH1 and TH2. Biochemistry. 1992; 31: 12190-7.
56. Lopez P.H., Schnaar R.L. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol. 2009; 19: 549-57.
57. Palmano K., Rowan A., Guillermo R., Guan J., McJarrow P. The role of gangliosides in neurodevelopment. Nutrients. 2015; 7: 3891-913.
58. Gurnida D.A., Rowan A.M., Idjradinata P., Muchtadi D., et al. Association of complex lipids containing gangliosides with cognitive development of 6-month-old infants. /Early Human Development. 2012; 88 (8): 595-601.
59. Wang B., McVeagh P., Petocz P., Brand-Miller J. Brain gangliosides and glycoprotein sialic acid in breastfed compared with formula-fed infants. Am J Clin Nutr. 2003; 78: 1024-9.
60. Xu X-Z, Zhu T-C. Effect of ganglioside in repairing the neurological function of children with cerebral palsy: analysis of the curative efficacy in 2230 cases. Chin J Clin Rehab. 2005; 9: 122-3 (in Chinese)